In renal cell carcinoma, Xiong et al. reported that RRM2 promotes sunitinib resistance and that knockdown of RRM2 enhances the anti-tumor efficiency of programmed cell death protein 1 (PD-1) blockade in renal cancer [36]. The gene discussed is PDCD1; the disease is renal carcinoma.